A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial
Thomas J. Povsic, John H. Alexander(Ohio State University Hospital), Roxana Mehran(Mount Sinai Hospital), Jan H. Cornel(Brigham and Women's Hospital), Christopher E. Buller(Teleflex (United States)), Gilles Montalescot(Maastricht University Medical Centre), Steven L. Zelenkofske(Novartis (Switzerland)), William A. Wargin(Ottawa Hospital), Diane Joseph‐McCarthy, Jarosław D. Kasprzak(Medical University of Lodz), Christopher P. Rusconi(University of North Carolina at Chapel Hill), Richard C. Becker(Clinical Research Institute), Christoph Bode(University Medical Center Freiburg), Mauricio G. Cohen(Santa Ana College)
Cited by 36
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k